TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00813176

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Double Lumen Endotracheal Tube

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Arndt Bronchial Blocker
Study: NCT04227054

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IMPEDE-FX Embolization Plug
Description: Fill an abdominal aortic aneurysm (AAA) sac outside of an endovascular aneurysm repair (EVAR) stent graft
Study: NCT00895011

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One dose 30 minutes prior to initiation of sexual activity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avanafil
Description: One dose 30 minutes prior to initiation of sexual activity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avanafil
Description: One dose 30 minutes prior to initiation of sexual activity
Study: NCT03656471

Intervention type: DEVICE
Intervention: clear aligners or fixed appliances
Description: Patients choose clear aligners or fixed appliances to treat their malocclusions

Intervention type: DEVICE
Intervention: clear aligners or fixed appliances
Description: Patients choose clear aligners or fixed appliances to treat their malocclusions
Study: NCT00052442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pralatrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pralatrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pralatrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pralatrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pralatrexate
Study: NCT00923364

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CTX, Cytoxan)
Description: 14.5 mg/kg intravenous (IV) (in the vein) infusion over 30 minutes once daily on days -6 and -5 (weight based dosing) or 50 mg/kg IV infusion over 2 hours on day -6 (weight based dosing) or 50/kg IV once daily x 2 doses on days +3 and +4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine(Fludara,Berlex Laboratories)
Description: 40 mg/m2 IV (in the vein) over 30 minutes (in the vein) once daily on Days -6, -5, -4, and -3 or 30 mg/m(2) IV over 30 minutes (in the vein) once daily on Days -6, -5, -4, -3, and -2

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation (TBI)
Description: 200 centigray (cGy) on Day -1 or 300 cGy on Day -1 (for 9/10 URD and Haplo patients)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell (HSC)
Description: stem cell transplant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Equine Anti-Thymocyte Globulin
Description: 30mg/kg IV (in the vein) once daily x 3 days on Days -6, -5, -4 (3 doses total)
Study: NCT01752036

Intervention type: RADIATION
Group type: OTHER
Intervention: Post-operative, Stereotactic Body Radiation Therapy (SBRT)
Description: All participants received SBRT at 600 cGy x 5 fractions
Study: NCT02816164

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neupogen
Description: Subcutaneous injections

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neupogen
Description: Subcutaneous injections
Study: NCT00270894

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epirubicin
Description: epirubicin (100 mg/m\^2) every 2 weeks for 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: cyclophosphamide (600 mg/m\^2) every 2 weeks for 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: docetaxel (75 mg/m\^2) every 2 weeks for 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: trastuzumab (6 mg/kg \[loading dose\] once then 4 mg/kg \[maintenance dose\]) every 2 weeks for 4 treatments
Study: NCT03933943

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3361237
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study: NCT03285815

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Proton Therapy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Proton Therapy
Study: NCT02816164

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neupogen
Description: Subcutaneous injections
Study: NCT01479218

Intervention type: DEVICE
Group type: OTHER
Intervention: Occlutech PDA occluder
Description: Four different sizes of Occluders will be evaluated based on pre-assessment of PDA size.
Study: NCT01465139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDX-301
Description: CDX-301, administered in multiple dosages and frequencies depending on arm:~n=3-6 at between 1-75 μg/kg over 5 days~n=3-6 at 25 μg/kg over 7 days~n=3-6 at 25 μg/kg over 10 days
Study: NCT03922802

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acute Intermittent Hypoxia + Non Invasive Spinal Cord Stimulation + Gait Training
Description: Subjects will receive up to 45 minutes of AIH prior to receiving transcutaneous electrical spinal cord stimulation delivered by a Transcutaneous Spinal Cord Neurostimulator while performing locomotor activities.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Acute Intermittent Hypoxia + Non Invasive Spinal Cord Stimulation + Gait Training
Description: Subjects will perform locomotor activities with transcutaneous electrical spinal cord stimulation after receiving sham acute intermittent hypoxia

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Acute Intermittent Hypoxia + Sham Non Invasive Spinal Cord Stimulation + Gait Training
Description: Subjects will perform locomotor activities with sham transcutaneous electrical spinal cord stimulation after receiving sham acute intermittent hypoxia
Study: NCT03661684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 40 mg po q day of Prednisone for 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 40 mg po q day of Prednisone for 3 days
Study: NCT02368470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemifloxacin-based triple therapy
Description: Rabeprazole (Rabiet®, ildong pharmaceutical Co. Ltd., Seoul, Korea) 20 mg twice daily, amoxicillin (Pamoxin®, Dongwha Co. Ltd., Seoul, Korea) 1 g twice daily, and gemifloxacin (Factive®, LG Life Sciences, Ltd, Seoul, Korea) 320 mg once daily for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard triple therapy
Description: Rabeprazole (Rabiet®, ildong pharmaceutical Co. Ltd., Seoul, Korea) 20 mg twice daily, amoxicillin (Pamoxin®, Dongwha Co. Ltd., Seoul, Korea) 1 g twice daily, and clarithromycin (Klaricid®, Abbot Korea Co. Ltd., Seoul, Korea) 500 mg twice daily for 7 days
Study: NCT02505048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rucaparib
Description: 600 mg bid per os , 28 day cycle, number of cycles: until progression or unacceptable toxicity develops.
Study: NCT02737046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon-Alfa-2b
Description: OPTIONAL: For subjects receiving interferon therapy at baseline, continue Interferon alfa-2b 5 million IU daily or pegylated interferon alfa-2b 1.5 μg/kg once weekly, subcutaneously (SQ) for up to 12 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon-Alfa-2b
Description: OPTIONAL: For subjects receiving interferon therapy at baseline, continue Interferon alfa-2b 5 million IU daily or pegylated interferon alfa-2b 1.5 μg/kg once weekly, subcutaneously (SQ) for up to 12 months.
Study: NCT03270462

Intervention type: DRUG
Group type: OTHER
Intervention: Envarsus XR
Description: Pilot study documenting the neurotoxic side effects including tremors in patients with stable graft who are receiving Tacrolimus (Envarsus XR) following kidney transplantation. Standardized questionnaire will be used to document these symptoms.
Study: NCT03333616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: is an immunotherapy medication that stimulates the immune system to fight cancer cells throughout the body.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab binds to and blocks the activation of PD-1. This results in the activation of T-cells and cell-mediated immune responses against tumor cells
Study: NCT00801164

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Frio Mouth Rinse Placebo
Description: Prescription Mouth Rinse. Rinse with 15ml twice daily then expectorate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Frio Mouth Rinse
Description: Prescription Mouth Rinse. Rinse with 15ml twice daily then expectorate.
Study: NCT04627467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine
Description: 250mg tablet (150mg base chloroquine)
Study: NCT01675765

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immunotherapy plus chemotherapy
Description: live attenuated double deleted Lm

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immunotherapy with cyclophosphamide plus chemotherapy
Description: live attenuated double deleted Lm
Study: NCT00687063

Intervention type: DRUG
Intervention: insulin detemir
Description: Start dose and frequency of insulin detemir is to be decided by physician. The choice of patient is also at the discretion of Physician
Study: NCT02608177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin
Description: Receives 4 weeks of study drug linagliptin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin
Description: Receives 4 weeks of study drug linagliptin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glipizide
Description: Receives 4 weeks of study drug glipizide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glipizide
Description: Receives 4 weeks of study drug glipizide
Study: NCT03818841

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula device
Description: Patients will be randomly allocated to this treatment

Intervention type: DEVICE
Group type: OTHER
Intervention: Non-rebreathing oxygen mask group
Description: Patients will be randomly allocated to this treatment
Study: NCT02322983

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control of Stress
Description: To control stress were measured (at different times: T1, T2, T3 and T4) Venham's Score, Heart Rate, Respiratory Rate, and the titration of gases.
Study: NCT03126305

Intervention type: OTHER
Intervention: OC-Go
Description: OC-Go, a HIPAA-compliant web-based clinician portal and patient-side mobile application that allows clinicians to create and push tailored treatment assignments to patients on their mobile devices
Study: NCT01467791

Intervention type: OTHER
Intervention: Observation
Description: Observe patients
Study: NCT03756272

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bupivacaine block
Description: stellate ganglion bupivacaine injection

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ganglion block
Description: stellate ganglion sodium chloride injection
Study: NCT00813215

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Meal challenge
Description: Meal challenge with a test meal rich on saturated fat.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Meal challenge
Description: Meal challenge with a test meal rich on saturated fat.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Meal challenge
Description: Meal challenge with a test meal rich on monounsaturated fat

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Meal challenge
Description: Meal challenge with a test meal rich on monounsaturated fat
Study: NCT02139839

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Lactobacillus capsules
Description: L. rhamnosus GR-1 and L. reuteri RC-14 capsules manufactured by Chr. Hansen

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lactobacillus capsules
Description: L. rhamnosus GR-1 and L. reuteri RC-14 capsules manufactured by Chr. Hansen

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gelatin pill
Description: Placebo Comparator capsules, identical in appearance to the active product; 98% Gelatin with no L. rhamnosus GR-1 and L. reuteri RC- 14.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo gelatin pill
Description: Placebo Comparator capsules, identical in appearance to the active product; 98% Gelatin with no L. rhamnosus GR-1 and L. reuteri RC- 14.
Study: NCT04175808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omecamtiv Mecarbil (OM)
Description: Oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omecamtiv Mecarbil (OM)
Description: Oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: 400 mg moxifloxacin oral tablet
Study: NCT01446094

Intervention type: DRUG
Group type: OTHER
Intervention: regadenoson
Description: Intravenous administration of 0.4 mg dose of Regadenoson using per routine CMR, as indicated in the package insert.
Study: NCT00871247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finasteride 5 mg Tablet, single dose
Description: A: Experimental Subjects received Intas Pharmaceuticals Ltd, India formulated products under fed conditions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Proscar® 5 mg Tablet, single dose
Description: B: Active comparator Subjects received Merck Sharp and Dohme, U.S.A formulated products under fed conditions
Study: NCT03309774

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: questionnaires
Description: Children with Complex Regional Pain Syndrome (CRPS) will be filled questionnaires before and after relaxation sessions. These questionnaire evaluate the quality of life and pain of child~There will be:~* Questionnaire KIDSCREEN 52~* Visual Analogue Scale (EVA)~* Neuropathic Pain 4 (DN4)~* Pain of the child Gustave Roussy (DEGR)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: holter electrocardiogram
Description: Children with Complex Regional Pain Syndrome (CRPS) will be have holter electrocardiogram before and after relaxation sessions.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: blood pressure
Description: Blood pressure of Children with Complex Regional Pain Syndrome (CRPS) will be measured by Nexfin monitor before and after relaxation sessions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: relaxation sessions
Description: Children with Complex Regional Pain Syndrome (CRPS) will be performed 20 relaxation sessions and 2 per week.~During relaxation sessions children will be recorded by voice recorder. Children should describe his feelings at the preceding session.~After every relaxation sessions children evaluate pain according to Eland Color Scale.
Study: NCT01191879

Intervention type: OTHER
Intervention: Blood test
Description: Blood test

Intervention type: OTHER
Intervention: Blood test
Description: Blood test
Study: NCT01910311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: Administered orally
Study: NCT01566812

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breast feeding optimization
Description: Breast feeding optimization program extends from late pregnancy period to 6 months after birth. Prenatal intervention consists of individual and group counseling/education; perinatal intervention consists of in-hospital lactation support; postnatal intervention consists of home visit, counseling session, reminding telephone call and bulk SMS, special counseling for working mothers, breast pump rental, occupational-related support

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Usual care applied in the hospital

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual care applied in the hospital
Study: NCT01847131

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxymetazoline
Description: 0.05% Oxymetazoline nasal sprays were commercially available.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo nasal spray
Description: Placebo nasal spray has made by the local pharmaceutical company in thailand who commercially manufacture and sell 0.05% oxymetazoline nasal spray. The placebo contains the same ingredients as the drug except the active ingredient.
Study: NCT03957460

Intervention type: OTHER
Intervention: SpHb monitoring
Description: Subjects receive the continuous and noninvasive hemoglobin monitoring (SpHb monitoring).
Study: NCT01129024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lusutrombopag
Description: tablet
Study: NCT03541915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mg (magnesium sulfate)
Description: 20mg/kg of magnesium sulfate will be infused after induction of anesthesia. And magnesium sulfated will be continuously infused at a rate of 15mg/kg/h during the operation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control (saline)
Description: The same volume of normal saline will be infused after induction of anesthesia and continuously infused at the same rate of magnesium.
Study: NCT03442868

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high frequency rTMS
Description: Participants receive 16 minutes (5Hz, 24 10-second trains with a inter-train interval of 30s) of high frequency rTMS applied to either primary motor cortex (M1), supplementary motor area (SMA) and dorsolateral prefrontal cortex (DLPFC) at different sessions. Walking performance is evaluated before and after the brain stimulation.
Study: NCT02279407

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo matching to Omega-3 carboxylic acids (olive oil)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega-3 carboxylic acids
Description: 4 g administered as 4 x 1 g capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega-3 carboxylic acids
Description: 4 g administered as 4 x 1 g capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: 10 mg administered as 10 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: 10 mg administered as 10 mg tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to dapagliflozin 10 mg
Study: NCT04617431

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile health application and social media
Description: The intervention involved reminding the intervention group to upload their dietary diary every day. The researchers were trained by a dietitian and provided suggestions about diet and exercise to the intervention group. LINE  is a mobile app operated by LINE Corporation. All users can use texts, images, video, and audio for contact at any time. A LINE group was created to deliver medical knowledge of diet and exercise. Each of the messages were guided by a diet manual for kidney disease (edited by Department of Dietetics, National Taiwan University Hospital Yunlin Branch). The intervention group also asked questions about CKD management, and a teleconsultation of health information was provided. A daily target of 7,500 steps was set and used to emphasize the correct concepts about exercise. Participants were inspired in the intervention group if someone achieved the target number of steps.
Study: NCT01868919

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Parenting Program
Description: Level 3 or 4 of Triple P
Study: NCT01843647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icotinib
Description: Patients receive 8-week icotinib induction treatment before surgery and 1-year icotinib adjuvant therapy after surgery.Icotinib is administered orally with a dose 125 mg 3 times daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: After surgery patients receive 4-cycle adjuvant chemotherapy with vinorelbine~/cisplatin regimen, until untolerable toxicity or disease progression.
Study: NCT02827656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decapeptyl
Description: luteal support as described and vaginal progesterone 200 mg 3 times a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hCG luteal support
Description: luteal support as described and vaginal progesterone 200 mg 3 times a day
Study: NCT02636140

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Light
Description: A brief, 1 minute exposure to light of varying color and intensity. The combination of color and intensity will be the same in all participants, but the order in which they are received is randomized.
Study: NCT03609593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Subjects will receive Bendamustine 50-90 mg/m2 on days 1-2 for three cycles with each cycle being 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax: 12 cycles~Venetoclax will then be started after 3 cycles of BR. Dosing for venetoclax will be in a step wise fashion as follows:~* Cycle 4 days 1-7 (Week 1): 20 mg once daily~* Cycle 4 days 8-14 (Week 2): 50 mg once daily~* Cycle 4 days 15-21 (Week 3): 100 mg once daily~* Cycle 4 days 22-28 (Week 4): 200 mg once daily~* Cycle 4 day 29 and thereafter (Week 5 and on): 400 mg once daily; continue until disease progression, unacceptable toxicity, or 12 cycles duration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: For cycles 1 through 3, subjects will receive BR on days 1 and 2. For cycles 5-10, subjects will receive rituximab monotherapy at 375 mg/m2 (cycle 5) or rituximab at 500 mg/m2 (cycles 6-10) on day 1 (or days 1 and 2 if split-dose).
Study: NCT03513848

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Retimer
Description: The Retimer light device in this study is a commercially-available wearable light device. It permits ambulation while receiving light from LEDs positioned below the eyes. The LEDs emit green light (\~500nm, 230 µW/m2, 500 lux), close to the peak sensitivity of circadian photoreceptors.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Retimer placebo
Description: The Retimer device has been dimmed to reduce the light intensity to a level that will not shift circadian timing.